This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meyer, D. L. Articles by Starling, J. J. Search for Related Content PubMed PubMed Citation Articles by Meyer, D. L. Articles by Starling, J. J.

Site-specific Prodrug Activation by Antibody-ß-Lactamase Conjugates: Regression and Long-Term Growth Inhibition of Human Colon Carcinoma Xenograft Models

Hybritech Incorporated, San Diego, California 92196-9006 [D. L. M., S. D. M., D. G. M.], and Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285 [L. N. J., K. L. L., T. A. S., S. L. B., J. J. S.]

Antibody-directed catalysis (ADC) is a two-step method for the delivery of chemotherapeutic agents in which enzyme-antibody conjugate, prelocalized to antigen-bearing tumor cells, catalyzes the site-specific conversion of prodrug to drug. An ADC system consisting of F(ab')-ß-lactamase conjugates and a cephalosporin derivative of the oncolytic agent 4-de-sacetylvinblastine-3-carboxhydrazide was investigated.

The ability of the system to mediate antitumor activity was compared with that of free drug given alone and with covalent drug-antibody conjugates in LS174T and T380 colon carcinoma xenografts in nude mice. Efficacy increased from moderate tumor growth inhibition by using free 4-desacetylvinblastine-3-carboxhydrazide to tumor regression and long-term stabilization with the ADC system. Labile covalent drug-antibody conjugates prepared from the same antibodies were less effective than ADC and required much higher antibody doses.

The antigens KS1/4, carcinoembryonic antigen, and tumor-associated glycoprotein-72, TAG-72, present on the model cell lines, were chosen to investigate the effect of differences in subcellular location and expression heterogeneity on the efficacy of ADC delivery. Response was equivalent with the three tumor antigens. Hence, heterogeneous expression and membrane shedding of carcinoembryonic antigen and TAG-72, did not diminish the suitability of these antigens as targets for ADC therapy. In contrast, drug-antibody conjugate efficacy was more sensitive to subcellular location and heterogeneity.

Thus, ADC is a highly effective form of immunochemotherapy in preclinical models, with applicability toward a variety of antigen targets.

¹ To whom requests for reprints should be addressed, at Hybritech, Inc., P.O. Box 269006, San Diego, CA 92196-9006.

Received 1/12/93. Accepted 6/18/93.

This article has been cited by other articles:

				F. A. Harding, A. D. Liu, M. Stickler, O. J. Razo, R. Chin, N. Faravashi, W. Viola, T. Graycar, V. P. Yeung, W. Aehle, et al. A {beta}-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy Mol. Cancer Ther., November 1, 2005; 4(11): 1791 - 1800. [Abstract] [Full Text] [PDF]

				M. Rooseboom, J. N. M. Commandeur, and N. P. E. Vermeulen Enzyme-Catalyzed Activation of Anticancer Prodrugs Pharmacol. Rev., March 1, 2004; 56(1): 53 - 102. [Abstract] [Full Text] [PDF]

				D. L. Meyer, J. Schultz, Y. Lin, A. Henry, J. Sanderson, J. M. Jackson, S. Goshorn, A. R. Rees, and S. S. Graves Reduced antibody response to streptavidin through site-directed mutagenesis Protein Sci., March 1, 2001; 10(3): 491 - 503. [Abstract] [Full Text]

				G. K. Smith, S. Banks, T. A. Blumenkopf, M. Cory, J. Humphreys, R. M. Laethem, J. Miller, C. P. Moxham, R. Mullin, P. H. Ray, et al. Toward Antibody-directed Enzyme Prodrug Therapy with the T268G Mutant of Human Carboxypeptidase A1 and Novel in Vivo Stable Prodrugs of Methotrexate J. Biol. Chem., June 20, 1997; 272(25): 15804 - 15816. [Abstract] [Full Text] [PDF]